2024-10-30
【Press release】STSP Bureau Partners with Companies at AusBiotech 2024 to Showcase Capabilities and Promote Biotechnology Industry Expansion!
Published by Investment Services Division
Southern Taiwan Science Park Bureau, National Science and Technology Council Press Release
STSP Bureau Partners with Companies at AusBiotech 2024 to Showcase Capabilities and Promote Biotechnology Industry Expansion!
Date: October 30, 2024
STSP Bureau Spokesperson: Deputy Director General Lin Hsiu-chen
Tel: +886 937-362-660
STSP Bureau Media Contact: Section Chief Ko Ting-ting
Tel: +886 989-266-992
AusBiotech is Australia's largest international biotechnology industry exhibition and features the AusPartnering one-on-one business matchmaking meetings, providing a platform for business collaboration for biotechnology and pharmaceutical professionals from Australia and worldwide. The Southern Taiwan Science Park (STSP) Bureau of the National Science and Technology Council, in collaboration with the Development Center for Biotechnology (DCB), is participating in AusBiotech 2024 from October 30 to November 1 at the Melbourne Convention and Exhibition Centre. Together with park-based companies, STSP aims to engage with international stakeholders and showcase Taiwan’s advancements in biotechnology. Deputy Director-General Lin Hsiu-Chen delivered a welcome opening at the Taiwan STSP Pavilion, joined by Hsu Yu-Tien, Representative of the Taipei Economic and Cultural Office in Australia, and AusBiotech Deputy CEO Rosanne Hyland, who extended their well-wishes for the success of the event and the robust growth of Taiwan’s biotechnology sector.
The Taiwan STSP Pavilion's exhibition theme is "Emerging Biotechnology and Cell Therapy" featuring five participating companies: KriSan Biotech specializes in process development and contract manufacturing services for complex small molecules, Antibody-Drug Conjugates (ADC), Peptide-Drug Conjugates (PDC), and Oligonucleotides, having provided over 114 products to global partners. Honya Medical is a cell therapy company focusing on stem cell preparation development and manufacturing, primarily targeting degenerative and aging-related diseases, including cardiovascular, renal, and metabolic diseases, respiratory diseases, and musculoskeletal disorders. GenMont Biotech has established a "Rapid Strain Screening Platform" and continues to develop functional probiotic ingredients and various health product series, while also offering development and contract manufacturing services. Syngen Biotech possesses core technologies in strain development and microbial fermentation, has passed international quality standard inspections, and complies with PIC/S GMP international API manufacturing standards which focus on developing functional ingredients and special formulation health products, with capabilities in development and contract manufacturing services. Ducolege Biotechnology utilizes Extre2Cold fish skin collagen extraction technology to obtain complete collagen from fish skin, reproducing fish skin's wound healing capabilities.
To maximize the impact of this exhibition, the STSP Bureau collaborated with the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of the Ministry of Economic Affairs, Taiwan’s Representative Office in Melbourne, and the Science and Technology Division, of the NSTC Representative Office in Australia, the Australian Office, and the Centre for Eye Research Australia (CERA), to hold the “Taiwan-Australia Biotechnology Forum” on October 28. This forum facilitated networking between Taiwanese companies and Australian biotechnology industry leaders to foster future bilateral cooperation. Special thanks were also extended to Emily Lee, Honorary President of the Taiwanese Chambers of Commerce in Oceania (TCCO), as well as Rick Liu, President of the Taiwanese Scholar Association of Australia (TSAA), Dr. John Jiang, and Dr. Tony Huang, for their valuable assistance in organizing this event.
By participating in this exhibition, park-based companies have gained increased international visibility, demonstrating their expertise in developing innovative biotechnology products and contract manufacturing services. On the opening day, distinguished representatives from the Australian Trade and Investment Commission (Austrade), the Government of Victoria, St. Vincent’s Hospital Melbourne - one of Australia’s top ten hospitals, the Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia’s global biopharmaceutical leader CSL, world leading CDMO PCI Pharma Services, and ASX-listed pharmaceutical manufacturing company IDT Australia visited the Taiwan STSP Pavilion. The pavilion attracted significant interest from international enterprises, creating substantial opportunities for global collaboration and highlighting the technological expertise of Taiwan’s biotechnology industry.
STSP Bureau Partners with Companies at AusBiotech 2024 to Showcase Capabilities and Promote Biotechnology Industry Expansion!
Date: October 30, 2024
STSP Bureau Spokesperson: Deputy Director General Lin Hsiu-chen
Tel: +886 937-362-660
STSP Bureau Media Contact: Section Chief Ko Ting-ting
Tel: +886 989-266-992
AusBiotech is Australia's largest international biotechnology industry exhibition and features the AusPartnering one-on-one business matchmaking meetings, providing a platform for business collaboration for biotechnology and pharmaceutical professionals from Australia and worldwide. The Southern Taiwan Science Park (STSP) Bureau of the National Science and Technology Council, in collaboration with the Development Center for Biotechnology (DCB), is participating in AusBiotech 2024 from October 30 to November 1 at the Melbourne Convention and Exhibition Centre. Together with park-based companies, STSP aims to engage with international stakeholders and showcase Taiwan’s advancements in biotechnology. Deputy Director-General Lin Hsiu-Chen delivered a welcome opening at the Taiwan STSP Pavilion, joined by Hsu Yu-Tien, Representative of the Taipei Economic and Cultural Office in Australia, and AusBiotech Deputy CEO Rosanne Hyland, who extended their well-wishes for the success of the event and the robust growth of Taiwan’s biotechnology sector.
The Taiwan STSP Pavilion's exhibition theme is "Emerging Biotechnology and Cell Therapy" featuring five participating companies: KriSan Biotech specializes in process development and contract manufacturing services for complex small molecules, Antibody-Drug Conjugates (ADC), Peptide-Drug Conjugates (PDC), and Oligonucleotides, having provided over 114 products to global partners. Honya Medical is a cell therapy company focusing on stem cell preparation development and manufacturing, primarily targeting degenerative and aging-related diseases, including cardiovascular, renal, and metabolic diseases, respiratory diseases, and musculoskeletal disorders. GenMont Biotech has established a "Rapid Strain Screening Platform" and continues to develop functional probiotic ingredients and various health product series, while also offering development and contract manufacturing services. Syngen Biotech possesses core technologies in strain development and microbial fermentation, has passed international quality standard inspections, and complies with PIC/S GMP international API manufacturing standards which focus on developing functional ingredients and special formulation health products, with capabilities in development and contract manufacturing services. Ducolege Biotechnology utilizes Extre2Cold fish skin collagen extraction technology to obtain complete collagen from fish skin, reproducing fish skin's wound healing capabilities.
To maximize the impact of this exhibition, the STSP Bureau collaborated with the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of the Ministry of Economic Affairs, Taiwan’s Representative Office in Melbourne, and the Science and Technology Division, of the NSTC Representative Office in Australia, the Australian Office, and the Centre for Eye Research Australia (CERA), to hold the “Taiwan-Australia Biotechnology Forum” on October 28. This forum facilitated networking between Taiwanese companies and Australian biotechnology industry leaders to foster future bilateral cooperation. Special thanks were also extended to Emily Lee, Honorary President of the Taiwanese Chambers of Commerce in Oceania (TCCO), as well as Rick Liu, President of the Taiwanese Scholar Association of Australia (TSAA), Dr. John Jiang, and Dr. Tony Huang, for their valuable assistance in organizing this event.
By participating in this exhibition, park-based companies have gained increased international visibility, demonstrating their expertise in developing innovative biotechnology products and contract manufacturing services. On the opening day, distinguished representatives from the Australian Trade and Investment Commission (Austrade), the Government of Victoria, St. Vincent’s Hospital Melbourne - one of Australia’s top ten hospitals, the Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia’s global biopharmaceutical leader CSL, world leading CDMO PCI Pharma Services, and ASX-listed pharmaceutical manufacturing company IDT Australia visited the Taiwan STSP Pavilion. The pavilion attracted significant interest from international enterprises, creating substantial opportunities for global collaboration and highlighting the technological expertise of Taiwan’s biotechnology industry.
- For further information, please contact ...MS LIN(#2160)
Attachment